aTyr Pharma (ATYR) Stock: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.12
-0.04 (-24.90%)
▼
5d:
-33.53%
30d:
-61.3%
90d:
-76.15%
WAIT
LOW Confidence
Analysis Updated: Oct 26, 2026 12:00 AM ET
Earnings: Nov 05, 2026
8d
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATYR is down 33.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATYR is down 33.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.12, which is considered oversold relative to its 30-day fair value range of $0.18 to $0.33.
Technical Outlook: Technically, ATYR is in a strong downtrend. Immediate support is located at $0.10, while resistance sits at $0.21. Short-term momentum is weak, with the stock down 24.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.86 (+1762.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATYR is in a strong downtrend. Immediate support is located at $0.10, while resistance sits at $0.21. Short-term momentum is weak, with the stock down 24.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.86 (+1762.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.18 -
$0.33
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-24.9%)
- BULLISH: Trading 1762.5% below Wall St target ($2.86)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.18 -
$0.33
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.10
Resistance Level
$0.21
Current Trend
Strong Downtrend
Technical data as of
Oct 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.35
Wall Street Target
$2.86
(+1762.5%)
Share & Embed Analysis
Last updated: October 27, 2026 2:13 PM ET
Data refreshes hourly during market hours. Next update: 3:13 PM
Data refreshes hourly during market hours. Next update: 3:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$259 | 64 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 56 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 58 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 72 BUY |
